知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.04 秒)

    ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES AS ANTINEOGENIC AGENTS
    2.
    发明申请
    ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES AS ANTINEOGENIC AGENTS 审中-公开
    工程化的原始CYSTINE / CYSTEINE降解酶作为原发性细胞因子

    公开(公告)号：US20150064160A1

    公开(公告)日：2015-03-05

    申请号：US14472779

    申请日：2014-08-29

    申请人： Board of Regents, The University of Texas System

    发明人： George GEORGIOU ,  Everett STONE

    IPC分类号： A61K45/06 ,  A61K38/51 ,  C12N9/88

    CPC分类号： A61K45/06 ,  A61K38/51 ,  C12N9/88 ,  C12Y404/01001

    摘要： Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.

    摘要翻译： 描述了与具有L-囊肿（e）降解酶活性的蛋白质的工程相关的方法和组合物。 例如，在某些方面，可以公开一种修饰的胱硫醚-γ-裂解酶，其包含一个或多个氨基酸取代并能够降解L-囊肿（e）。 此外，本发明的某些方面提供了使用所公开的蛋白质或核酸来治疗具有L-囊肿（e）的癌症的组合物和方法。

    Stringent selectable markers
    3.
    发明授权
    Stringent selectable markers 有权
    严格的可选标记

    公开(公告)号：US09284563B2

    公开(公告)日：2016-03-15

    申请号：US13378006

    申请日：2010-06-15

    申请人： Arie Pieter Otte ,  Henricus Johannes Maria Van Blokland ,  John Antonius Verhees

    发明人： Arie Pieter Otte ,  Henricus Johannes Maria Van Blokland ,  John Antonius Verhees

    IPC分类号： C12N15/65 ,  C12N15/67 ,  C12N15/52 ,  C12N15/85

    CPC分类号： C12N15/65 ,  C12N15/52 ,  C12N15/67 ,  C12N15/85 ,  C12N2840/102 ,  C12N2840/206 ,  C12Y404/01001

    摘要： The present invention relates to nucleic acid constructs comprising selectable marker genes in a multicistronic transcription unit for use in the generation and selection of eukaryotic host cells for expression of a gene product of interest. For increased stringency of selection, the coding sequence of the selectable marker may be directed preceded by a relatively short functional open reading frame to reduce the efficiency of translation of the selectable marker, and/or the amino acid sequence of the selectable marker may comprise one or more mutations that reduce the level of resistance provide by the mutated marker as compared to its wild type counterpart. The invention further relates to methods for generating eukaryotic host cells for expression of a gene product of interest, wherein these nucleic acid constructs are used, and to methods for producing a gene product of interest wherein thus generated host cells are applied.

    摘要翻译： 本发明涉及包含用于产生和选择用于表达感兴趣的基因产物的真核宿主细胞的多顺反子转录单位中的选择性标记基因的核酸构建体。 为了增加选择的严格性，选择性标记的编码序列之前可以有较短的功能性开放阅读框，以降低选择性标记的翻译效率，和/或可选择标记的氨基酸序列可以包含一个 或更多的突变，其降低与其野生型对应物相比由突变标记提供的抗性水平。 本发明还涉及用于产生用于表达目标基因产物的真核宿主细胞的方法，其中使用这些核酸构建体，以及用于产生感兴趣的基因产物的方法，其中施用了由此产生的宿主细胞。

    METHIONINE METABOLITES PREDICT AGGRESSIVE CANCER PROGRESSION
    4.
    发明申请
    METHIONINE METABOLITES PREDICT AGGRESSIVE CANCER PROGRESSION 审中-公开
    甲硫氨酸代谢物预防癌症进展

    公开(公告)号：US20150204882A1

    公开(公告)日：2015-07-23

    申请号：US14617016

    申请日：2015-02-09

    申请人： CEDARS-SINAI MEDICAL CENTER

    发明人： Neil A. Bhowmick ,  Diptiman Choudhury

    IPC分类号： G01N33/68 ,  G01N27/327 ,  C12Q1/00 ,  C12N9/88

    CPC分类号： G01N33/6815 ,  C12N9/88 ,  C12Q1/005 ,  C12Y402/01022 ,  C12Y404/01001 ,  G01N2333/90 ,  G01N2333/988 ,  G01N2800/54

    摘要： The invention relates to the use of enzymes, nanorods, and nanoelectronic devices to detect cysteine level in a patient sample and relates to the use of the detected cysteine level to predict cancer recurrence in the patient and to prescribe and/or administer an appropriate therapy to a subject. The invention is directed to systems and methods of detecting cysteine level in a sample from a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention is directed to systems and methods of predicting the probability of a recurrence of a cancer in a subject, wherein the systems or methods can further comprise measuring at least one additional parameter, such as PSA level, Gleason score and clinical stage. The invention further comprises prescribing and/or administering an appropriate therapy to a subject based on the predicted probability of recurrence.

    摘要翻译： 本发明涉及使用酶，纳米棒和纳米电子器件来检测患者样品中的半胱氨酸水平，并且涉及使用检测到的半胱氨酸水平来预测患者的癌症复发，并开出和/或施用适当的治疗方法 课程。 本发明涉及检测来自受试者的样品中的半胱氨酸水平的系统和方法，其中所述系统或方法还可包括测量至少一个附加参数，例如PSA水平，Gleason评分和临床分期。 本发明涉及预测受试者中癌症复发概率的系统和方法，其中所述系统或方法还可包括测量至少一个附加参数，例如PSA水平，Gleason评分和临床分期。 本发明还包括基于所预测的复发概率向受试者处方和/或施用适当的治疗。

    ENGINEERED PRIMATE L-METHIONINASE FOR THERAPEUTIC PURPOSES
    8.
    发明申请
    ENGINEERED PRIMATE L-METHIONINASE FOR THERAPEUTIC PURPOSES 有权
    用于治疗用途的工程化的主要L-甲硫氨酸酶

    公开(公告)号：US20170044514A1

    公开(公告)日：2017-02-16

    申请号：US15297102

    申请日：2016-10-18

    申请人： Board of Regents, The University of Texas System

    发明人： George GEORGIOU ,  Everett STONE ,  Wei-Cheng LU

    IPC分类号： C12N9/88

    CPC分类号： C12N9/88 ,  A61K35/12 ,  A61K38/51 ,  A61K45/06 ,  C12N1/14 ,  C12N1/20 ,  C12N5/0601 ,  C12N15/70 ,  C12N15/74 ,  C12N15/79 ,  C12Y404/01001 ,  A61K2300/00

    摘要： Methods and compositions relating to the engineering of an improved protein with methionine-γ-lyase enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-γ-lyase (CGL) comprising one or more amino acid substitutions and capable of degrading methionine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with methionine depletion using the disclosed proteins or nucleic acids.

    摘要翻译： 描述了与具有甲硫氨酸-γ-裂解酶活性的改进蛋白质的工程相关的方法和组合物。 例如，在某些方面，可以公开包含一个或多个氨基酸取代并能降解甲硫氨酸的修饰的胱硫醚-γ-裂解酶（CGL）。 此外，本发明的某些方面提供使用所公开的蛋白质或核酸用于用甲硫氨酸消耗治疗癌症的组合物和方法。